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Abstract
Introduction
The prevalence of hypoalbuminemia, early changes of plasma albumin (P-Alb) levels, and
their effects on mortality in cardiogenic shock are unknown.
Materials and methods
P-Alb was measured from serial blood samples in 178 patients from a prospective multina-
tional study on cardiogenic shock. The association of hypoalbuminemia with clinical charac-
teristics and course of hospital stay including treatment and procedures was assessed. The
primary outcome was all-cause 90-day mortality.
Results
Hypoalbuminemia (P-Alb < 34g/L) was very frequent (75%) at baseline in patients with car-
diogenic shock. Patients with hypoalbuminemia had higher mortality than patients with nor-
mal albumin levels (48% vs. 23%, p = 0.004). Odds ratio for death at 90 days was 2.4 [95%
CI 1.5–4.1] per 10 g/L decrease in baseline P-Alb. The association with increased mortality
remained independent in regression models adjusted for clinical risk scores developed for
cardiogenic shock (CardShock score adjusted odds ratio 2.0 [95% CI 1.1–3.8], IABP-
SHOCK II score adjusted odds ratio 2.5 [95%CI 1.2–5.0]) and variables associated with
hypoalbuminemia at baseline (adjusted odds ratio 2.9 [95%CI 1.2–7.1]). In serial measure-
ments, albumin levels decreased at a similar rate between 0h and 72h in both survivors and
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nonsurvivors (ΔP-Alb -4.6 g/L vs. 5.4 g/L, p = 0.5). While the decrease was higher for
patients with normal P-Alb at baseline (p<0.001 compared to patients with hypoalbumine-
mia at baseline), the rate of albumin decrease was not associated with outcome.
Conclusions
Hypoalbuminemia was a frequent finding early in cardiogenic shock, and P-Alb levels
decreased during hospital stay. Low P-Alb at baseline was associated with mortality inde-
pendently of other previously described risk factors. Thus, plasma albumin measurement
should be part of the initial evaluation in patients with cardiogenic shock.
Trial registration
NCT01374867 at ClinicalTrials.gov.
Introduction
Hypoalbuminemia is a frequent finding both in chronic illness[1] and acute conditions[2]. In
chronic illness hypoalbuminemia has been attributed to decreased albumin synthesis due to
wasting and cachexia[3,4], although recent literature suggests that increased catabolism is
more often the cause[5]. In acute conditions the mechanisms contributing to hypoalbumine-
mia differ from chronic disease as the major cause of hypoalbuminemia in the acute setting is
capillary leakage into the interstitial space due to inflammatory processes[6]. In addition,
decreased synthesis, haemodilution due to fluid administration, renal and gut losses due to
congestion, and increased catabolism also play a role[5,7,8].
The association of hypoalbuminemia with increased mortality has been described in detail
for end-stage renal disease[9] but it has also been established in varied conditions such as
trauma[10], critical illness[7], cancer[11], chronic heart failure[12,13] as well as in the elderly
[14]. More recently, the role of albumin has attracted attention also in acute cardiac condi-
tions. Hypoalbuminemia has been shown to be associated with an increase in the rate of com-
plications[15,16] and long-term mortality[16] in acute myocardial infarction, as well as worse
outcomes in acute heart failure[17–19].
Cardiogenic shock is the most severe form of acute heart failure characterized by a low car-
diac output resulting in low blood pressure and hypoperfusion[20]. The most common cause
of cardiogenic shock is acute myocardial infarction[21]. Inflammatory and neurohormonal
responses play a central role in the pathophysiology of cardiogenic shock[22], but the preva-
lence of hypoalbuminemia and its effect on mortality remains unexplored.
The purpose of this study was to investigate the prevalence and prognostic significance of
plasma albumin (P-Alb) in patients with cardiogenic shock. Furthermore, we explored factors
associated with hypoalbuminemia and changes in albumin levels during hospitalization.
Materials and methods
The CardShock study (NCT01374867 at www.clinicaltrials.gov) is a European prospective,
observational, multicentre and multinational study on cardiogenic shock. Recruitment was
conducted between October 2010 and 31 December 2012. The study enrolled patients from
emergency departments, cardiac and intensive care units, as well as catheter laboratories in
nine tertiary hospitals from eight countries. The study was approved by the following ethics
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committees: Athens: Ethics Committee of Attikon University Hospital; Barcelona: Health
Research Ethics Committee of the Hospital de Sant Pau; Brescia: Ethics Committee of the
Province of Brescia; Brno: Ethic committee of University Hospital Brno; Helsinki: The Ethics
Committee, Department of Medicine, The Hospital District of Helsinki and Uusimaa; Porto:
Ethics committee of S. João Hospital Center/Porto Medical School; Rome: Ethical Committee
Sant’Andrea Hospital; Warsaw: Local Bioethics Committee of the Institute of Cardiology.
Copenhagen: The study was approved by the Danish Protection Agency with reference num-
ber GEH-2014-013; I-Suite number: 02731. The study was conducted in accordance with the
Declaration of Helsinki. Written informed consent was obtained from the patient or next of
kin if the patients were unable to give the consent on admission.
Inclusion criteria and data collection
Consecutive patients aged over 18 years were enrolled in the study within 6 hours from identi-
fication of cardiogenic shock. The inclusion criteria were (1) an acute cardiac cause for the
shock, and (2) systolic blood pressure <90mmHg (after adequate fluid challenge) for 30min or
a need for vasopressor therapy to maintain systolic blood pressure >90mmHg, and (3) signs of
hypoperfusion (any of the following: altered mental status, cold periphery, oliguria <0.5mL/
kg/h for the previous 6 h, or blood lactate >2 mmol/L) (for details see Harjola et al.[21]).
Exclusion criteria were shock caused by ongoing hemodynamically significant arrhythmia or
shock after cardiac or non-cardiac surgery. The etiology of cardiogenic shock was determined
by local investigators. Acute coronary syndrome etiology was defined as shock caused by myo-
cardial infarction (with or without ST-elevation). Echocardiography was performed per proto-
col at study entry. Patients were treated according to local practice, and treatment and
procedures were registered.
The study cohort consists of 178 patients with plasma samples available at baseline. Blood
was drawn within 3 hours of study enrollment. Additionally, serial blood samples were col-
lected at 12 h, 24 h, 36 h, 48 h and 72h (all +/-3 h). Separated plasma was immediately frozen
in aliquots and stored at −80˚C. Creatinine, C-reactive protein (CRP), high-sensitivity tropo-
nin T (hsTnT), N-terminal pro b-type natriuretic peptide (NT-proBNP), alanine aminotrans-
ferase, alkaline phosphatase, total bilirubin, and albumin (P-Alb) (Roche Diagnostics, Basel,
Switzerland) were analyzed from the plasma samples at a central accredited laboratory
(ISLAB, Kuopio, Finland). The reference limit used for hypoalbuminemia was<34 g/L as rec-
ommended by the central laboratory, and has also been used in several studies on heart failure
[12,13,18,23]. Arterial blood lactate and haemoglobin were analysed locally. Estimated glomer-
ular filtration rate (eGFR) was calculated from creatinine values using the CKD-EPI (Chronic
Kidney Disease Epidemiology Collaboration) equation[24]. Central venous pressure was
recorded at 72 hours in 65 patients with a central venous line.
The primary endpoint was all-cause 90-day mortality. Vital status during follow-up was
determined through direct contact with the patient or next of kin, or through population and
hospital registers. Two patients were lost to follow-up. The study was approved by local ethics
committees and conducted in accordance with the Declaration of Helsinki.
Statistical analysis
Results are presented as numbers (n) and percentages (%), means and standard deviations
(SD) for normally distributed variables, or median and interquartile range (IQR) for variables
with a skewed distribution. Categorical variables were compared using Chi-squared or Fisher’s
exact test whereas Mantel-Haenszel trend test was used for ordinal variables. Between-group
comparisons were performed using two-way analysis of variance, Student’s t-test or Mann–
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Whitney U-test, as appropriate. Associations between continuous variables were assessed
using Pearson and Spearman correlations for normally and non-normally distributed vari-
ables, respectively. Differences in survival between groups were assessed by Kaplan–Meier sur-
vival curves and log-rank test. The significance of changes in albumin levels between different
time points was tested using a paired-samples T-test. Logistic regression analysis was used to
identify variables associated with baseline hypoalbuminemia. To determine baseline variables
independently associated with hypoalbuminemia, variables with a univariable p<0.10 were
entered into a multivariable logistic regression model. For the selection of independently asso-
ciated variables, both forward and backward conditional and likelihood ratio models were
used. Receiver operating characteristics analysis was used to select the multivariable model
with the highest area under the curve for predicting baseline hypoalbuminemia. Multivariable
logistic regression models were used to test for the independent association between plasma
albumin and 90-day mortality. Multivariable adjustments were made for 1) variables statisti-
cally significantly associated with hypoalbuminemia at baseline (p<0.05), i.e. smoking status,
comorbidities (heart failure with reduced ejection fraction, coronary artery disease, prior myo-
cardial infarction), calcium-channel blocker use, lung oedema on X-ray, BMI, eGFR, haemo-
globin, NT-proBNP, and CRP at baseline, and presence of multi-vessel disease in primary
coronary angiography, as well as 2) contemporary risk prediction models in cardiogenic shock
such as the CardShock risk score[21], the IABP-SHOCK II score[25], and combinations of 1)
and 2). To assess whether incorporating plasma albumin to the multivariable model provided
incremental prognostic value, the likelihood ratio test for nested models was used. Discrimina-
tion was also assessed by integrated discrimination index (IDI) and clinical risk stratification
by net reclassification improvement (NRI) [26]. Results from the regression analyses are pre-
sented as odds ratios (ORs) with 95% confidence intervals (CIs). A two-sided p-value <0.05
was regarded statistically significant. Data were analyzed using the SPSS statistical package,
version 23 (IBM Corp, Armonk, NY) with the exception of the reclassification analyses which
were performed with R version 3.5.1[27] using packages Hmisc and pROC.
Results
Patient characteristics
The mean age in the cohort was 66 years, and 26% were women. On average, mean arterial
pressure at inclusion was 57 (SD 11) mmHg. The most common etiology of cardiogenic shock
was acute coronary syndrome (ACS) (80%). The overall 90-day all-cause mortality was 42%.
The mean baseline P-Alb was 29.5 g/L (SD 6.4 g/L, range 11–42 g/L). Hypoalbuminemia
(P-Alb <34 g/l) at admission was observed in 75% (134/178) of patients. There was no differ-
ence in the P-Alb levels at baseline between ACS and non-ACS etiologies of cardiogenic shock
(P-Alb 29.8 g/L vs. 28.3 g/L, p = 0.7)
Characteristics of hypoalbuminemic cardiogenic shock patients
Baseline characteristics and clinical presentation of patients with and without hypoalbuminemia
are shown in Table 1. Compared to patients with normal P-Alb levels, hypoalbuminemic
patients were more likely to have a history of chronic diseases, such as prior myocardial infarc-
tion, ischemic heart disease, heart failure, and worse renal function. There were fewer current
smokers and less use of calcium channel blockers in the hypoalbuminemic group. Notably, BMI
was lower in the hypoalbuminemic group compared to the group with normal albumin levels.
As shown in Table 2, there were no differences in lactate, mean arterial pressure, or systolic
blood pressure between the groups. However, patients with hypoalbuminemia were more
likely to have pulmonary oedema on chest X-ray, as well as higher levels of NT-proBNP and
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CRP, and lower levels of haemoglobin at baseline. There were no significant differences in
liver function tests (alanine aminotransferase, alkaline phosphatase and total bilirubin) at base-
line. In multivariable analysis, independent associates of hypoalbuminemia were higher CRP
at baseline, pulmonary oedema on chest X-ray, history of heart failure with reduced ejection
fraction, older age and calcium channel blocker use prior to admission (Table 3). Coronary
angiography was performed in 136 patients, in which patients with hypoalbuminemia were
more likely to have multi-vessel disease. Post-PCI, a higher proportion of patients with hypoal-
buminemia had a TIMI grade flow of less than 3, but the difference was not statistically
significant.
Table 1. Patient characteristics and mortality in normoalbuminemic and hypoalbuminemic cardiogenic shock patients.
All Normoalbuminemia Hypoalbuminemia p-value
(P-Alb�34g/L) (P-Alb <34 g/L)
Demographics (n = 178) (n = 44) (n = 134)
Age, years; mean (SD) 66 (12) 64 (12) 67 (12) 0.10
Smoking 72 (41) 23 (54) 49 (37) 0.05
Women 46 (26) 33 (29) 13 (20) 0.20
BMI, kg/m2; mean (SD) 27.0 (4) 28.2 (4) 26.6 (4) 0.03
Medical history
Hypertension 108 (61) 29 (66) 79 (59) 0.41
Coronary artery disease 58 (33) 9 (21) 49 (37) 0.05
Previous myocardial infarction 45 (25) 5 (11) 40 (30) 0.01
Prior CABG 11 (6) 1 (2) 10 (8) 0.30
History of HFrEF 22 (13) 1 (2) 21 (16) 0.02
Diabetes mellitus 53 (30) 9 (21) 44 (33) 0.12
Medications in use at admission
ACEI 53 (30) 15 (34) 37 (28) 0.51
ARB 26 (15) 6 (14) 20 (15) 0.81
Calcium-channel blockers 22 (12) 10 (23) 13 (10) 0.04
Beta-blocker 67 (38) 14 (32) 53 (40) 0.42
Diuretics 53 (31) 11 (26) 42 (32) 0.45
Clinical presentation
Cold periphery 170 (96) 40 (93) 130 (97) 0.24
Confusion 117 (67) 29 (66) 88 (67) 0.93
Oliguria 94 (54) 24 (55) 70 (53) 0.90
Lactate > 2 125 (71) 29 (66) 96 (73) 0.35
ACS etiology 143 (80) 38 (86) 105 (78) 0.25
Lung oedema on X-ray 60 (36) 10 (23) 50 (40) 0.04
Systolic BP, mmHg; mean (SD) 77 (12) 76 (12) 79 (13) 0.52
Mean arterial pressure, mmHg; mean (SD) 57 (11) 58 (12) 57 (10) 0.43
Heart rate, beats/min; mean (SD) 88 (29) 87 (30) 89 (29) 0.77
LVEF, %; mean (SD) 33 (14) 35 (13) 32 (14) 0.09
Time from detection of shock to baseline, h:min; median (IQR) 2:00 (0:22–4:00) 2:00 (0:00–4:03) 2:00 (0:30–3:30) 0.86
Mortality
90-day mortality 74 (42) 10 (23) 64 (48) 0.004
Results shown as n (%) for categorical and mean (SD) or median (IQR) for continuous variables. ACEI = angiotensin-converting enzyme inhibitor; ACS = acute
coronary syndrome; ALT = alanine aminotransferase; ARB = angiotensin receptor blocker; BMI = body mass index; BP = blood pressure; CABG = coronary artery
bypass grafting; HFrEF = heart failure with reduced ejection fraction; IQR = interquartile range; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal
prohormone of B-type natriuretic peptide; SD = standard deviation
https://doi.org/10.1371/journal.pone.0217006.t001
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Hypoalbuminemia and outcome
Hypoalbuminemia at baseline was associated with a higher 90-day mortality compared to nor-
mal P-Alb levels (48% vs 23%, p = 0.004; Fig 1). Fig 2 shows that 90-day mortality increased
across P-Alb quartiles from 23% in the highest quartile to 57% in the lowest quartile (p<0.001
for trend).
In unadjusted logistic regression analysis, baseline P-Alb had an OR of 2.4 per 10 g/L decre-
ment (95% CI 1.5–4.1, p = 0.001). Multivariable adjustment did not significantly alter the
results. Lower baseline albumin was associated with mortality independently of the CardShock
risk score, the IABP-SHOCK II score and the variables associated with hypoalbuminemia
(Table 4). Addition of P-Alb improved the risk prediction model compared with either the
Table 2. Laboratory test results and angiographic findings in normoalbuminemic and hypoalbuminemic cardiogenic shock patients.
All Normoalbuminemia (P-Alb�34g/
L)
Hypoalbuminemia (P-Alb <34
g/L)
p-value
Laboratory test results at baseline (n = 178) (n = 44) (n = 134)
eGFR, ml/min/1.73m2); mean (SD) 63 (30) 69 (26) 60 (30) 0.04
NT-proBNP, ng/L; median
(IQR)
2710
(585–9434)
866
(226–5029)
3769
(1037–11745)
<0.001
CRP, mg/L; median (IQR) 16 (4–54) 7 (2–19) 25 (5–75) <0.001
Leukocytes, 10E9; mean (SD) 14.0 (5.4) 14.7 (6.0) 13.8 (5.3) 0.30
Hemoglobin, g/L; mean (SD) 129 (23) 139 (20) 125 (23) <0.001
Albumin (g/L), mean (SD) 29.5 (6.4) 37.2 (2.3) 27.0 (5.1)
Lactate (mmol/L); median (IQR) 2.7
(1.7–5.8)
2.4
(1.5–5.1)
2.9
(1.7–5.9)
0.15
hsTnT (ng/L); median (IQR) 2260 (398–
5418)
2601 (386–6940) 2108 (403–5362) 0.69
Alanine aminotransferase (IU/L); median (IQR) 44 (20–92) 42 (22–86) 45 (20–103) 0.90
Alkaline phosphatase (IU/L); median (IQR) 61 (49–81) 67 (53–91) 60 (47–78) 0.11
Total bilirubin (umol/L); median (IQR) 9.6 (5.7–15.4) 10.0 (5.6–16.1) 9.5 (5.7–15.2) 0.95
Change in albumin between baseline and 72h (ΔAlb 0-72h) (g/L);
mean (SD)
-5.0 (6.4) -10.2 (6.2) -2.5(4.7) <0.001
Fluid balance at 72h (ml); mean (SD) 1389 (4241) 1765 (4215) 692 (4116) 0.19
Angiographic findings (n = 136) (n = 36) (n = 100)
Multivessel disease; n (%) 93 (68) 18 (50) 75 (75) 0.006
TIMI flow <3 post PCI 37 (30) 6 (18) 31 (35) 0.06
PCI complications 44 (28) 12 (29) 32 (27) 0.77
Results shown as n (%) for categorical and mean (SD) or median (IQR) for continuous variables. CRP = C-reactive protein; eGFR = estimated glomerular filtration rate;
IQR = interquartile range; NT-proBNP = N-terminal prohormone of B-type natriuretic peptide; PCI = percutaneous coronary intervention; SD = standard deviation;
TIMI = thrombolysis in myocardial infarction
https://doi.org/10.1371/journal.pone.0217006.t002
Table 3. Factors independently associated with hypoalbuminemia at baseline.
Odds ratio 95% CI p-value
CRP at baseline; mg/L 1.02 1.003–1.03 0.01
Lung oedema on chest X-ray 2.9 1.2–7.1 0.02
History of HFrEF 11.7 1.4–98 0.02
Age; years 1.04 1.01–1.07 0.02
Use of calcium-channel blocking medication 0.3 0.1–0.9 0.03
CI = confidence interval; HFrEF = geart failure with reduced ejection fraction
https://doi.org/10.1371/journal.pone.0217006.t003
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CardShock risk score or the IABP-SHOCK II score alone (χ2 = 5.301, p = 0.02 and χ2 = 7.088,
p = 0.008 for comparison of nested models, respectively). Discrimination was also assessed
using integrated discrimination index (IDI) and clinical risk stratification by net reclassifica-
tion improvement (NRI) (Table 5).
Serial P-Alb measurements and changes during hospitalization
Plasma albumin concentrations decreased during hospitalization, on average -5.0 g/L during
the first 72 hours (ΔAlb0-72h). Albumin levels decreased similarly in survivors and non-survi-
vors (-4.6 g/L vs. 5.4 g/L, p = 0.5, Fig 3A). The P-Alb levels were lower for non-survivors
throughout the follow-up period of 72 hours compared to 90-day survivors. The downward
trend in P-Alb from baseline until 72h was statistically significant for both survivors and non-
survivors (p<0.001 for both). P-Alb decreased more rapidly among patients with normal
P-Alb at baseline compared with hypoalbuminemic patients (Table 2, Fig 3B). However, P-Alb
decrease (ΔAlb0-72h) was not associated with mortality, even after adjustment for baseline
P-Alb (OR 1.0, 95% CI 0.94–1.06, p = 0.87, adjusted for baseline albumin OR 0.94, 95% CI
Fig 1. Kaplan-Meier survival curves of 90-day mortality according to baseline plasma albumin (P-Alb).
https://doi.org/10.1371/journal.pone.0217006.g001
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0.87–1.02, p = 0.17). At 72 h, ΔAlb0-72h correlated negatively with fluid balance (Pearson
correlation coefficient (rp) = -0.41, p<0.001) and with CRP (Spearman correlation coefficient
(rs) = -0.41, p<0.001), but positively with alkaline phosphatase (rs = 0.28, p = 0.002) and total
bilirubin (rs = 0.26, p = 0.005). The negative correlation with central venous pressure at 72h
had borderline significance (rp = -0,26, p = 0.051).
Discussion
This is the first study on the prevalence and prognostic value of P-Alb in cardiogenic shock.
First, low P-Alb was a frequent finding (75%) early in cardiogenic shock, with most of the
Fig 2. 90-day mortality by baseline albumin quartiles. The P-Alb ranges for the quartiles were 34.0–42.9 g/L for the
1st quartile, 30.0–33.9 g/L for the 2nd quartile, 25.9–29.9 g/L for the 3rd quartile and 10.4–25.9 g/L for the 4th quartile.
https://doi.org/10.1371/journal.pone.0217006.g002
Table 4. Unadjusted and adjusted odds ratios for baseline plasma albumin with 90-day mortality.
Baseline plasma albumin per 10
g/L decrease
95% CI p-
value
Unadjusted OR 2.4 1.5–4.1 0.001
Adjusted with variables associated with hypoalbuminemiaa OR 2.9 1.2–7.1 0.02
Adjusted with CSS scoreb OR 2.0 1.1–3.8 0.03
Adjusted with CSS scoreb and variables associated with
hypoalbuminemiaa
OR 2.9 1.02–
8.4
0.045
Adjusted with IABP-SHOCK II scorec OR 2.5 1.2–5.0 0.01
Adjusted with IABP-SHOCK II scorec and variables associated
with hypoalbuminemiaa
OR 7.4 1.7–
31.3
0.007
OR = odds ratio; CI = confidence interval
aComorbidities (heart failure with reduced ejection fraction, ischaemic heart disease), smoking status, calcium-
channel blocker use, lung oedema on X-ray, body mass index, haemoglobin, NT-proBNP and CRP at baseline,
presence of multi-vessel disease in primary coronary angiography
bage >75 years (1 point), history of myocardial infarction or coronary bypass (1 point), altered mental status at
presentation (1 point), ACS etiology (1 point), left ventricular ejection fraction <40% (1 point), lactate (2–4 mmol/
l = 1 point, >4 mmol/l = 2 points) and estimated glomerular filtration rate on admission (60–30 mL/min/1.73 m2 = 1
point, <30 mL/min/1.73 m2 = 2 points)
cAge >73 years (1 point), history of stroke (1 point), blood glucose >10.6 g/L at baseline (1 point), creatinine >132.6
umol/L at baseline (1 point), TIMI flow <3 post-PCI (2 points), blood lactate >5 mmol/L (2 points)
https://doi.org/10.1371/journal.pone.0217006.t004
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patients having values below 30 g/L already at baseline. Second, hypoalbuminemia was associ-
ated with higher mortality independent of other variables. Third, P-Alb levels decreased dur-
ing hospitalization in all patients, but the rate of change was not associated with 90-day
Table 5. Comparison of cardiogenic shock risk score models.
Model AUC (95% CI) Continuous NRI (95% CI) IDI (95% CI)
CardShock risk score 0.798 (0.734–0.862)
CardShock risk score + P-Alb 0.819 (0.757–0.881) 0.297 (-0.006–0.600) 0.027 (0.003–0.051)
IABP II SHOCK -score 0.719 (0.629–0.808)
IABP II SHOCK -score + P-Alb 0.750 (0.661–0.839) 0.355 (-0.004–0.715) 0.054 (0.013–0.095)
AUC = area under curve; CI = confidence interval; IDI = integrated discrimination index; NRI = net reclassification
index; P-Alb = baseline plasma albumin
https://doi.org/10.1371/journal.pone.0217006.t005
Fig 3. A: Mean plasma albumin at different time points during hospitalization in 90-day survivors and non-
survivors of cardiogenic shock. Mean change between 0 and 72h -4.6 g/L for survivors, -5.4 g/L for non-survivors;
p = 0.54. B: Plasma albumin at different time points during hospitalization in patients with normoalbuminemia
or hypoalbuminemia at baseline. Mean change between 0 and 72 h -10.8 mg/L for normoalbuminemic patients and
-2.5 mg/L for hypoalbuminemic patients; p<0.001. P-values in the picture represent results for linear mixed model
analysis of variance for repeated measures. � p<0.05 § p<0.10 for the difference in P-Alb between groups at this time
point (Student’s t-test). Error bar = standard deviation.
https://doi.org/10.1371/journal.pone.0217006.g003
Hypoalbuminemia in cardiogenic shock
PLOS ONE | https://doi.org/10.1371/journal.pone.0217006 May 16, 2019 9 / 14
mortality. Nevertheless, plasma albumin levels were lower in non-survivors compared to survi-
vors during the duration of the study period.
The high proportion of hypoalbuminemic patients in this study was striking, and probably
has various causes. First, the association of hypoalbuminemia with comorbidities suggests that
hypoalbuminemia may be a pre-existing condition, perhaps linked with frailty and nutritional
status, as the lower hemoglobin levels and BMI in the hypoalbuminemic group could suggest.
Second, it has been suggested that hypoalbuminemia might predispose STEMI patients to car-
diogenic shock[16], which would lead to a higher prevalence of hypoalbuminemia in cardio-
genic shock populations (75% in our study compared to 30% in STEMI[16]). Furthermore,
inflammatory response and SIRS in cardiogenic shock[28] increase capillary permeability pro-
moting the transcapillary escape rate of albumin[6]. Interestingly, hypoalbuminemia did not
appear to be linked to the severity of cardiogenic shock, as for example lactate or blood pres-
sure levels did not differ between normo- and hypoalbuminemic patients.
Hypoalbuminemia has been shown to be associated with worse outcomes in acute coronary
syndromes[15,16], acute heart failure[17,18] and critical illness[7,29,30]. We show that in car-
diogenic shock mortality increases in a linear fashion with decreasing baseline P-Alb levels.
Patients with normal albumin levels at baseline had a relatively favourable outcome, whereas
moderate or severe hypoalbuminemia was associated with two-fold higher mortality. In a
meta-analysis of hypoalbuminemia in acutely ill patients, it was estimated that each 10 g/L
decrease in serum albumin concentration increased the odds of mortality by 137%[2]. In line
with this estimation the unadjusted odds of 90-day mortality increased by 140% for each 10g/l
decrement in our study, and lower albumin levels were significantly associated with mortality
in analyses adjusted for multiple covariates.
The independent association of hypoalbuminemia with mortality suggests that hypoalbu-
minemia may have effects on mortality which are not explained by other variables interacting
with hypoalbuminemia. Oduncu et al. suggested that hypoalbuminemia may play a direct role
in poor reperfusion after PCI[16]. Interestingly in this respect, albumin has been suggested to
have anticoagulative properties[29]. It has also been implied that albumin may be associated
with disease severity instead of just the presence or absence of disease, in which case categoriz-
ing pre-existing diseases as binary variables may lead to attributing the risk caused by disease
severity to albumin[1]. In our study, there was a trend for TIMI flow <3 after primary PCI in
hypoalbuminemic patients, however, the presence of multi-vessel coronary artery disease did
not interfere with the independent association of P-Alb with mortality.
There are several possible pathways to explain the association between hypoalbuminemia,
cardiogenic shock, outcome and the laboratory parameters associated with hypoalbuminemia
in this study, such as lower hemoglobin and higher CRP-values, which may act in concert.
One possible explanation could be aggressive fluid resuscitation prior to study enrollment and
congestion leading to worse outcomes. Unfortunately, we do not have available data on fluid
resuscitation prior to study enrollment to assess this possibility, but after study enrollment the
fluid balance between normo- and hypoalbuminemic patients did not differ. Another possible
pathway could be pre-existing chronic illness resulting in low-grade inflammation raising
CRP, which would lead to anemia of chronic illness and hypoalbuminemia[31]. Also, infection
or higher levels of inflammation reflected by the higher CRP-levels in hypoalbuminemic
patients could lead to capillary leakage of albumin resulting in hypoalbuminemia[6].
In this study, there was no association between the rate of decrease in P-Alb during the first
72 hours and 90-day mortality. The significance of changes in albumin has been explored in
ICU patients, but data are conflicting [7, 28]. We found that the rate of decrease of P-Alb was
associated with the baseline level and differed between normo- and hypoalbuminemic patients.
Correlations between ΔAlb0-72h and CRP, Bilirubin and AFOS at 72 hours also suggest that
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inflammation and cholestatic liver injury may play a role in the rate of decrease of P-Alb in
cardiogenic shock.
The high prevalence of hypoalbuminemia and its independent association with outcome
suggests that measuring P-Alb levels early in cardiogenic shock should be incorporated in clin-
ical practice. As can be seen in Fig 3A, low P-Alb at later time points was also associated with
mortality, but the association was strongest for early albumin levels (0-12h). As discussed
above, albumin levels are subject to change due to various reasons and the rate of change did
not predict mortality. As intravenous use of albumin has been shown not to decrease mortality
in the critically ill [32], further studies are needed to determine if there are any other therapeu-
tic options that would specifically target the worse prognosis associated with hypoalbumine-
mia in cardiogenic shock.
Our study has some limitations. First, it was not possible to have data on the patients’ albu-
min levels before study enrollment to determine whether the observed hypoalbuminemia was
pre-existing or not. Second, we did not have information on the fluid status prior to study
enrollment, as haemodilution due to excessive fluid resuscitation could be one of the causes of
hypoalbuminemia. Third, although adjustments were made for various variables found to
associate with hypoalbuminemia, there may be confounding factors we were unable to account
for, leading to an overestimation of the independent association of P-Alb with mortality. How-
ever, the estimated ORs are in accordance with previous studies on the effect of hypoalbumine-
mia on mortality and the results were consistent in multiple analyses.
Conclusions
In conclusion, hypoalbuminemia was a very frequent finding in the early phase of cardiogenic
shock. P-Alb at baseline was independently associated with 90-day all-cause mortality, with
mortality increasing across lower albumin quartiles. This study found that P-Alb is a prognos-
tic marker in cardiogenic shock, and we suggest incorporating P-Alb measurement as part of
the assessment of patients with cardiogenic shock.
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